HMV Wealth Advisors LLC Trims Stock Position in Eli Lilly and Company $LLY

Key Points

• HMV Wealth Advisors LLC reduced its holdings in Eli Lilly and Company by 47.3%, selling 759 shares during the 2nd quarter, which left them with a total of 845 shares valued at approximately $659,000.
• Wall Street analysts have adjusted their price targets for Eli Lilly, with Morgan Stanley lowering theirs to $1,023.00 and JPMorgan Chase setting a new target of $1,050.00, while the consensus rating remains a "Moderate Buy".
• CEO David A. Ricks and Director J Erik Fyrwald both purchased significant amounts of Eli Lilly stock, highlighting confidence from insiders despite recent market fluctuations.

HMV Wealth Advisors LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 47.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 845 shares of the company's stock after selling 759 shares during the period. HMV Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $659,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter worth about $27,000. Citizens National Bank Trust Department lifted its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $40,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research note on Friday. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Finally, Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $938.94.

Insiders Place Their Bets

In related news, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $845.40 on Tuesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The firm has a market capitalization of $800.14 billion, a P/E ratio of 55.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a fifty day simple moving average of $735.35 and a two-hundred day simple moving average of $765.48. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the company earned $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.